- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
3 Humongous Health-Care Stocks This Week презентация
Содержание
- 1. 3 Humongous Health-Care Stocks This Week
- 2. A lot of health-care stocks took a
- 3. Shares of the biopharmaceutical firm soared 22%
- 4. Positive phase 1 preliminary data was announced
- 5. Shares of the biotech climbed 18% higher
- 6. Specialty pharmaceutical company Mallinckrodt (NYSE: MNK) is
- 7. Shares of the clinical-stage biotech jumped nearly
- 8. No big announcements this week from Bio-Path.
- 9. Questcor won’t shoot up significantly, since the
- 10. Find out which stock The Motley Fool’s
A lot of health-care stocks took a beating this week. Not all of them, though. Here are the three most humongous health-care stocks over the week ending April 11, 2014. 1
Слайд 2A lot of health-care stocks took a beating this week. Not
all of them, though.
Here are the three most humongous health-care stocks over the week ending April 11, 2014.
Here are the three most humongous health-care stocks over the week ending April 11, 2014.
1
2
3
Слайд 3Shares of the biopharmaceutical firm soared 22% this week.
Agios Pharmaceuticals
(Nasdaq: AGIO)
Source: Yahoo! Finance
Слайд 4Positive phase 1 preliminary data was announced for cancer drug AG-221.
Agios
reported AG-221 was well tolerated but with two possible drug-related severe adverse events.
Clinical results were promising, with multiple complete remissions in patients with blood cancer.
Celgene (Nasdaq: CELG) stands as another winner, as AG-221 is part of a collaboration established between the big biotech and Agios in 2010.
Clinical results were promising, with multiple complete remissions in patients with blood cancer.
Celgene (Nasdaq: CELG) stands as another winner, as AG-221 is part of a collaboration established between the big biotech and Agios in 2010.
Why Agios shares took off
Слайд 5Shares of the biotech climbed 18% higher for the week.
Questcor
Pharmaceuticals (Nasdaq: QCOR)
Source: Yahoo! Finance
Слайд 6Specialty pharmaceutical company Mallinckrodt (NYSE: MNK) is acquiring Questcor.
Shareholders will receive
$30 in cash and 0.897 Mallinckrodt shares for each Questcor share they own.
The deal represents a 27% premium over Questcor’s closing price before the announcement.
The deal represents a 27% premium over Questcor’s closing price before the announcement.
Why Questcor shot up
Слайд 7Shares of the clinical-stage biotech jumped nearly 18% this week.
Bio-Path
Holdings (Nasdaq: BPTH)
Source: Yahoo! Finance
Слайд 8No big announcements this week from Bio-Path.
The biotech looks to be
rebounding from a sell-off that started in late February.
Bio-Path’s Liposomal Grb-2 is in phase 1 clinical studies targeting several forms of leukemia and myelodysplastic syndrome.
Bio-Path’s Liposomal Grb-2 is in phase 1 clinical studies targeting several forms of leukemia and myelodysplastic syndrome.
Why Bio-Path boomed
Слайд 9Questcor won’t shoot up significantly, since the price of the acquisition
by Mallinckrodt is set.
Bio-Path Holdings could continue its rebound, but major new developments are still in the future.
Agios’ early-stage results for AG-221 show considerable promise .
The partnership with Celgene gives Agios a leg up in continued development of the blood cancer drug.
A possibility also exists that Celgene could use some of its $5.6 billion in cash and short-term investments to scoop up Agios down the road.
Bio-Path Holdings could continue its rebound, but major new developments are still in the future.
Agios’ early-stage results for AG-221 show considerable promise .
The partnership with Celgene gives Agios a leg up in continued development of the blood cancer drug.
A possibility also exists that Celgene could use some of its $5.6 billion in cash and short-term investments to scoop up Agios down the road.
Best pick to stay humongous?
?
Слайд 10Find out which stock The Motley Fool’s chief investment officer selected
as the top pick for 2014 in our free report!
